News | June 03, 2022
Evonik to build new lipid production facility for mRNA-based therapies in U.S.
Construction will begin in early 2023, and the plant is scheduled to go onstream in 2025
Construction will begin in early 2023, and the plant is scheduled to go onstream in 2025
It is part of the company's CAD $30 million capital investment in the Aurora, Canada site
Revolutionary ovarian cancer rapid test available Q4 2022
The plant is expected to start commercial operations from Q4FY24
Under the terms of the agreement, Bachem will provide the appropriate engineering infrastructure and expertise to implement Lilly’s novel oligonucleotide manufacturing technology
A separate global Phase 3 study of S-217622 is underway aiming to recruit participants globally to support regulatory filings this year
U GRO Capital is a listed MSME lending fintech platform
To meet the growing global demand for respiratory active pharmaceutical ingredients (APIs), Inke is to invest €9 million into its production plant to reinforce focus on inhalation micronised APIs
This partnership allows both companies to become first movers to bridge an inevitable gap with the largest organizations in the pharmaceutical, nutraceutical, cosmetic, and veterinary sectors
The company also plans to expand the facility
Subscribe To Our Newsletter & Stay Updated
